E-DRUG: orphan cancers and drug development (cont)
--------------------------------------------------
I had sent the mail below to Blaine Carmichael, not being sure it would be
of particular interest to e-druggers generally. However, reading Jatinder
Singh's message and the comments of WB, I thought it might be useful to
seek the comments of e-druggers, if any.
In the meantime I can add another terminology one frequently finds these
days i.e "Abandoned drugs"
Let us keep our focus on one common value: "It is a fundamental right that
when any one gets ill, they must have access to safe and effective
treatment"
Murtada M Sesay
____________________Forward Header_____________________
Hello
Just a few thoughts to share with you:
Will "orphan" diseases/drugs always remain so? What happens if their status
changes? (i.e increase in disease burden and therefore market size?)
This also leads me to the issue of pricing. What are the current mechanisms
for ensuring affordability, considering the incentives given to
developers?
Do you think it would be useful to streamline terminology just in case
this becomes an increasingly big issue.
I identify a number of expressions in my reading:
Orphan products
Rare diseases
Orphan disorders
Orphan designated products
Do these and others need clarification or just semantics?
Regards
Murtada M Sesay
Essential Drugs and Other Medicines Department
WHO
Geneva
Switzerland
Tel 022 41 791 3676
e-mail sesaym@who.int
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.